What is the address of PARAPHARMACIE BASUNGA?

The registered office of PARAPHARMACIE BASUNGA is located at Elsense Steenweg 43A, 1050 Elsene.

Is PARAPHARMACIE BASUNGA still active?

Yes. According to the CBE (3 October 2026) PARAPHARMACIE BASUNGA is active, legal situation “Normale toestand”, started on 21 December 2017.

Is PARAPHARMACIE BASUNGA registered on Peppol?

Yes, PARAPHARMACIE BASUNGA is registered on the Peppol network with ID 0208:0686711104.

What is the enterprise number of PARAPHARMACIE BASUNGA?

The enterprise number of PARAPHARMACIE BASUNGA is BE0686711104.

When was PARAPHARMACIE BASUNGA founded?

PARAPHARMACIE BASUNGA was founded on 21 December 2017.

Who are the directors of PARAPHARMACIE BASUNGA?

According to the 2025 annual accounts, the directors of PARAPHARMACIE BASUNGA are: CLAUDE BASUNGA.

Is PARAPHARMACIE BASUNGA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PARAPHARMACIE BASUNGA make in 2025?

PARAPHARMACIE BASUNGA recorded a loss after taxes of € 1,188 in financial year 2025.

What is the revenue of PARAPHARMACIE BASUNGA?

As a small company, PARAPHARMACIE BASUNGA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -1,039.

PARAPHARMACIE BASUNGA (Private Limited) - Elsene

Dossier PARAPHARMACIE BASUNGA, printed on 3 October 2026 from databakkes.be/en/0686711104/parapharmacie-basunga. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

PARAPHARMACIE BASUNGA from Elsene, company number BE0686711104, closed financial year 2025 with a result of € -1,188 after tax. For that financial year PARAPHARMACIE BASUNGA recorded a gross margin of € -1,039 and equity of € 12,124. Compared with financial year 2024, the result moved from € -2,607 to € -1,188. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 15, 2026.

What it is worth Healthy

€ 12,124

▼ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1,188

▲ 54 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 8,970

▼ 28% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -276.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 333

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -1,431 Gross margin 2022: € -1,431 First fiscal year in the series	€ -1,813 Gross margin 2023: € -1,813 ▼ € 382 vs 2022 (€ -1,431) Unfavourable step	€ -2,409 Gross margin 2024: € -2,409 ▼ € 596 vs 2023 (€ -1,813) Unfavourable step	€ -1,039 Gross margin 2025: € -1,039 ▲ € 1,370 vs 2024 (€ -2,409) Favourable step	▲ € 1,370
Profit after taxes	€ -1,563 Profit after taxes 2022: € -1,563 First fiscal year in the series	€ -1,957 Profit after taxes 2023: € -1,957 ▼ € 394 vs 2022 (€ -1,563) Unfavourable step	€ -2,607 Profit after taxes 2024: € -2,607 ▼ € 650 vs 2023 (€ -1,957) Unfavourable step	€ -1,188 Profit after taxes 2025: € -1,188 ▲ € 1,419 vs 2024 (€ -2,607) Favourable step	▲ € 1,419
Equity	€ 17,876 Equity 2022: € 17,876 First fiscal year in the series	€ 15,919 Equity 2023: € 15,919 ▼ 11% vs 2022 (€ 17,876) Unfavourable step	€ 13,312 Equity 2024: € 13,312 ▼ 16% vs 2023 (€ 15,919) Unfavourable step	€ 12,124 Equity 2025: € 12,124 ▼ 9% vs 2024 (€ 13,312) Unfavourable step	▼ 9%
Total debts	€ 5,646 Total debts 2022: € 5,646 First fiscal year in the series	€ 5,013 Total debts 2023: € 5,013 ▼ 11% vs 2022 (€ 5,646) Favourable step	€ 399 Total debts 2024: € 399 ▼ 92% vs 2023 (€ 5,013) Favourable step	€ 333 Total debts 2025: € 333 ▼ 17% vs 2024 (€ 399) Favourable step	▼ 17%
Cash	€ 22,264 Cash 2022: € 22,264 First fiscal year in the series	€ 19,826 Cash 2023: € 19,826 ▼ 11% vs 2022 (€ 22,264) Unfavourable step	€ 12,501 Cash 2024: € 12,501 ▼ 37% vs 2023 (€ 19,826) Unfavourable step	€ 8,970 Cash 2025: € 8,970 ▼ 28% vs 2024 (€ 12,501) Unfavourable step	▼ 28%
Retained profit	€ 5,476 Retained profit 2022: € 5,476 First fiscal year in the series	€ 3,519 Retained profit 2023: € 3,519 ▼ 36% vs 2022 (€ 5,476) Unfavourable step	€ 912 Retained profit 2024: € 912 ▼ 74% vs 2023 (€ 3,519) Unfavourable step	€ -276 Retained profit 2025: € -276 ▼ € 1,188 vs 2024 (€ 912) Unfavourable step	▼ € 1,188
Balance sheet total	€ 23,523 Balance sheet total 2022: € 23,523 First fiscal year in the series	€ 20,932 Balance sheet total 2023: € 20,932 ▼ 11% vs 2022 (€ 23,523) Unchanged	€ 13,711 Balance sheet total 2024: € 13,711 ▼ 34% vs 2023 (€ 20,932) Unchanged	€ 12,457 Balance sheet total 2025: € 12,457 ▼ 9% vs 2024 (€ 13,711) Unchanged	▼ 9%

Key figures of PARAPHARMACIE BASUNGA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PARAPHARMACIE BASUNGA?

What happened at PARAPHARMACIE BASUNGA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 15, 2026 New annual accounts for financial year 2025: loss of € 1,188. Source: NBB ↗
Jan 1, 2018 New establishment in Elsene. KBO
2017 CLAUDE BASUNGA became a director. NBB
Dec 21, 2017 Start of the company according to the CBE. KBO

In short

From € 1,563 loss in 2022 to € 1,188 loss in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at PARAPHARMACIE BASUNGA? We notify you, reason included.

Follow PARAPHARMACIE BASUNGA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit